Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

Shares of Madrigal Pharmaceuticals MDGL lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises only its ...

根据提交给美国证券交易委员会的Form 4文件显示，Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL)的总法律顾问Kelley Shannon T最近出售了公司股票。Shannon于1月17日以平均每股273.41美元的价格出售了277股，总价值约75,734美元。这笔交易发生之际，这家市值63.9亿美元的公司股票在过去一周下跌了13%以上，尽管过去一年仍保持3 ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

$MDGL insiders have traded $MDGL stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Shares of Madrigal Pharmaceuticals MDGL lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises ...